Inactive Instrument

News Auris Medical Holding AG Nasdaq

Equities

CH0249375764

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

Altamira Therapeutics Announces Publication of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis in Top Peer Reviewed Journal	Apr. 24	AQ
Altamira Therapeutics Ltd. Announces Publication of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis in Top Peer Reviewed Journal	Apr. 24	CI
Altamira Therapeutics : Notice of the Annual General Meeting of Shareholders of Altamira Therapeutics Ltd. (the “Company”) to be held on May 16, 2024 - Form 6-K	Apr. 16	PU
Transcript : Altamira Therapeutics Ltd., 2023 Earnings Call, Apr 10, 2024	Apr. 10
Altamira Therapeutics Provides Business Update, Reports Full Year 2023 Financial Results	Apr. 10	AQ
Altamira Therapeutics Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 10	CI
Altamira Therapeutics to Host Full Year 2023 Financial Results and Business Update Call on April 10, 2024	Apr. 04	AQ
Sector Update: Health Care Stocks Decline Late Afternoon	Mar. 25	MT
Top Midday Gainers	Mar. 25	MT
Sector Update: Health Care Stocks Softer in Afternoon Trading	Mar. 25	MT
Altamira, Univercells Partner to Test mRNA Vaccine Delivery; Shares Surge	Mar. 25	MT
Altamira Therapeutics Announces Collaboration with Univercells Group on Nanoparticle-Delivered mRNA Vaccines	Mar. 25	AQ
Altamira Therapeutics Ltd. Announces Collaboration with Univercells Group on Nanoparticle-Delivered mRNA Vaccines	Mar. 25	CI
Altamira Therapeutics’ Peptide-Based Delivery Platform Shown to Enhance Potency of Commonly Used Gene Delivery Method as Published in Peer-Reviewed Journal	Feb. 07	AQ
Altamira Therapeutics? Peptide-Based Delivery Platform Shown to Enhance Potency of Commonly Used Gene Delivery Method as Published in Peer-Reviewed Journal	Feb. 07	CI
Altamira Files Second Provisional Patent Application in Cancer Treatment; Shares Rise	Jan. 24	MT
Altamira Therapeutics Files Second Provisional Patent Application for OligoPhore Nanoparticles Targeting Different KRAS Mutations in Cancer Treatment	Jan. 24	AQ
Altamira Therapeutics Files Second Provisional Patent Application for OligoPhore Nanoparticles Targeting Different KRAS Mutations in Cancer Treatment	Jan. 24	CI
Altamira Therapeutics to Present at 3rd Annual mRNA-Based Therapeutics Summit	Jan. 08	AQ
Altamira Therapeutics Back in Compliance with Nasdaq Minimum Bid Price Rules	Dec. 29	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Auris Medical Holding AG Nasdaq

Equities

CH0249375764

Summary

Filters